Patents by Inventor James Copp

James Copp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPTP-BETA INHIBITORS
    Publication number: 20210130341
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Application
    Filed: October 2, 2020
    Publication date: May 6, 2021
    Inventors: John Janusz, James Copp, Kevin Peters
  • HPTP-Beta inhibitors
    Patent number: 10858354
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 8, 2020
    Assignee: Aerpio Pharmaceuticals, Inc.
    Inventors: John Janusz, James Copp, Kevin Peters
  • HPTP-BETA INHIBITORS
    Publication number: 20180354937
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Application
    Filed: May 7, 2018
    Publication date: December 13, 2018
    Inventors: John Janusz, James Copp, Kevin Peters
  • HPTP-? inhibitors
    Patent number: 9994560
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 12, 2018
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: John Janusz, James Copp, Kevin Peters
  • HPTP-BETA INHIBITORS
    Publication number: 20150259335
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: John Janusz, James Copp, Kevin Peters